Takeda presents additional Phase 3 clinical insights on investigational TYK2 inhibitor zasocitinib (TAK-279) at AAD 2026
Takeda has announced new data, presented at the 2026 American Academy of Dermatology (ADD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). Approximately 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 and a sig